Related Experiment Videos
Nodular lymphocyte predominant Hodgkin's lymphoma
Neelam Siddiqui1, Abdulrahman I Al-Diab
1Division of Oncology, Department of Medicine (38), College of Medicine, King Khalid University Hospital, PO Box 2925, Riyadh 11461, Kingdom of Saudi Arabia. neelamsiddiqui@hotmail.com
Saudi Medical Journal
|March 17, 2005
Summary
Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) in Saudi patients shows a distinct profile with early-stage disease and excellent initial response to treatment. However, a tendency for relapse highlights the need for ongoing therapeutic evaluation.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a distinct subtype of Hodgkin's lymphoma.
- Understanding its clinicopathological features in diverse populations is crucial for effective management.
Purpose of the Study:
- To delineate the clinicopathological characteristics, treatment strategies, outcomes, and sequelae of NLPHL patients within the Saudi population.
- To compare these findings with international data.
Main Methods:
- A retrospective review was conducted on 29 patients diagnosed with lymphocyte predominant Hodgkin's lymphoma between 1985 and 2000.
- Histological confirmation and subtyping were performed using hematoxylin and eosin staining and immunohistochemistry.
- Clinical data, including presentation, stage, treatment, and outcomes, were analyzed.
Main Results:
- Twenty-two cases were confirmed as NLPHL, predominantly affecting males (18/22) with a median age of 25 years.
- Most patients (86%) presented with early-stage disease (Ann Arbor I/II) and peripheral lymphadenopathy.
- All evaluable patients (16/16) achieved complete response to initial therapy, though four later relapsed.
Conclusions:
- NLPHL in Saudi patients shares similarities with Western cohorts, exhibiting a characteristic clinical and pathological profile.
- The disease course is notable for excellent initial treatment response but a significant tendency for relapse.
- Current treatment approaches may require modification based on emerging insights into NLPHL's molecular pathogenesis.